CD274 and cancer: There are several biomarkers associated with the response to anti-PD-1/anti-PD-L1 therapy including T cell infiltration, mutant genome, circulating extracellular vesicles, and circulating soluble PD-L1 expression, etc. In addition, we expect RT-PCR to replace IHC as a CDx method for cancer patients.